Key Insights on Gross Profit: Grifols, S.A. vs Bausch Health Companies Inc.

Grifols vs Bausch: A Decade of Gross Profit Trends

__timestampBausch Health Companies Inc.Grifols, S.A.
Wednesday, January 1, 201460089000001699214000
Thursday, January 1, 201578538000001930998000
Friday, January 1, 201670630000001912291000
Sunday, January 1, 201761760000002152011000
Monday, January 1, 201860290000002049560000
Tuesday, January 1, 201962510000002341232000
Wednesday, January 1, 202057780000002255165000
Friday, January 1, 202160400000001962596000
Saturday, January 1, 202257600000002231530000
Sunday, January 1, 202361980000002322701000
Loading chart...

In pursuit of knowledge

A Comparative Analysis of Gross Profit Trends: Grifols, S.A. vs Bausch Health Companies Inc.

In the ever-evolving pharmaceutical landscape, understanding financial health is crucial. This analysis delves into the gross profit trends of two industry giants, Grifols, S.A. and Bausch Health Companies Inc., from 2014 to 2023. Over this period, Bausch Health consistently outperformed Grifols, with an average gross profit nearly three times higher. Notably, Bausch Health peaked in 2015, achieving a gross profit 30% above its 2022 figure. Meanwhile, Grifols demonstrated steady growth, with a notable 37% increase from 2014 to 2023. Despite fluctuations, both companies showed resilience, with Grifols closing the gap slightly in recent years. This financial journey highlights the dynamic nature of the pharmaceutical sector, where strategic decisions and market conditions play pivotal roles in shaping profitability.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025